When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis.

John TM, Jacob CN, Kontoyiannis DP. · 2021

Read When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. by John TM, Jacob CN, Kontoyiannis DP. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8071133.txt.

Introduction

John and co-authors review why uncontrolled diabetes and severe COVID-19 form a perfect storm for mucormycosis. This mold infection has turned up again and again in COVID-19 patients. The team gathered every published case they could find. The total came to 41 cases with enough detail to judge. Risk factors, symptoms, and outcomes were then compared.

Diabetes appeared in 94% of the cases, and it was poorly controlled in 67% of those. Severe or critical COVID-19 showed in 95% of the patients. Most infections hit the nose, eyes, and brain, as they do in diabetes alone. Nearly all cases, 93%, were proven by firm criteria. That sets them apart from COVID-linked aspergillosis, where proof stays thin. The authors urge high suspicion in diabetic patients with rhino-orbital signs.

Catalog record

CREATORJohn TM, Jacob CN, Kontoyiannis DP.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE19 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8071133

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis By Teny M John, Ceena N Jacob, Dimitrios P Kontoyiannis, Michaela Lackner Published in: Journal of Fungi DOI: 10.3390/jof7040298 ABSTRACT Abstract Mucormycosis (MCR) has been increasingly described in patients with coronavirus disease 2019 (COVID-19) but the epidemiological factors, presentation, diagnostic certainty, and outcome of such patients are not well described. We review the published COVID-19-associated mucormycosis (CAMCR) cases (total 41) to identify risk factors, clinical features, and outcomes. CAMCR was typically seen in patients with diabetes mellitus (DM) (94%) especially the ones with poorly controlled DM (67%) and severe or critical COVID-19 (95%). Its presentation was typical of MCR seen in diabetic patients (mostly rhino-orbital and rhino-orbital-cerebral presentation). In sharp contrast to reported COVID-associated aspergillosis (CAPA) cases, nearly all CAMCR infections were proven (93%). Treating physicians should have a high suspicion for CAMCR in patients with uncontrolled diabetes mellitus and severe COVID-19 presenting with rhino-orbital or rhino-cerebral syndromes. CAMR is the convergence of two storms, one of DM and the other of COVID-19. Keywords: COVID-19, diabetes mellitus, mucormycosis 1. INTRODUCTION Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome virus 2 (SARS-CoV-2), has affected more than 130 million people worldwide, accounting for over 2.8 million deaths on the day of this report. Although aspergillosis has been reported to complicate severe COVID-19 (the entity is coined COVID-19-associated aspergillosis or CAPA), the pathophysiology and the true incidence of CAPA remains debatable, as very few CAPA cases are biopsy-documented [1,2]. In addition, Mucorales infections are emerging as a matter of concern in COVID-19, as poorly controlled diabetes mellitus (DM) and other co-morbidities are risk factors for both severe COVID-19 and mucormycosis (MCR) [3] and the use of corticosteroids to treat severe/critical COVID-19 is a well-known risk factor for MCR [4]. To that end, we reviewed the cases of MCR in patients with COVID-19, discuss the pathophysiology of MCR in the setting of COVID-19 and contrast the firmness of COVID-19-associated mucormycosis (CAMCR) to the ambiguities of CAPA diagnosis. 2. MATERIALS AND METHODS We searched PubMed (1 December 2019–9 April 2021) using the search terms “COVID-19”, “SARS CoV-2”, “novel coronavirus infection”, and “mucormycosis”, ”Mucorales”, “non-aspergillus mold”, “Mucor”, “Rhizopus”, “Rhizomucor”, “Cunninghamella”, and “Lichtehimia” (“Absidia”). We included only cases or case series reports containing adequate information about risk factors, clinical presentation, course, diagnosis, treatment, and outcome. Proven MCR was defined as per the EORTC-MSG criteria [5]. Since “probable” invasive fungal disease (IFD) in EORTC/MSG criteria applies only to immunocompromised hosts, we adapted the proposed definitions for CAPA to further define “probable” and “putative” MCR cases [6]. Patients who had a syndrome consistent with MCR such as rhino-orbital disease, with a positive culture from the nasal cavity were considered to have “probable” MCR. Patients with COVID-19 and cavitary pneumonia with the isolation of Mucorales from respiratory secretions were considered to have “putative” MCR. Mucormycosis was considered “concurrent” if evidence of infection was present on admission and “sequential” if a diagnosis was made 72 h after COVID-19 diagnosis. 3. RESULTS We identified 43 such patients; 41 cases with documented MCR (proven in 38, probable in 3, Table 1) and 2 putative cases (see Supplementary Table S1 and references). We identified five patients with rhino-orbital disease, and one patient with rhino-orbital-cerebral disease, which was not included as there was no culture or histopathology documentation, given the fact that COVID-19 rarely can mimic rhino-orbital disease due to ophthalmic vein thrombosis [7]. Thirty-four (83%) were males with a median age of 55 years (IQR 46–61). More than two-thirds of the patients (29/41, 71%) were reported from India. Although 40 (40/41, 98%) patients had risk factors for severe COVID-19, only two patients had EORTC risk factors for IFD. Of the 35 patients with information on glycemic status, 33 (33/35, 94%) had DM, with a mean HbA1C of 10 (in patients who had an HbA1c value available), and 22 (22/33, 67%) had uncontrolled DM before admission; three (3/33, 9%) patients had new-onset DM. Of the eighteen patients with DM and report of blood glucose and acid status, 8 (8/18, 44%) were in diabetic ketoacidosis (DKA) at the time of presentation. Among the 22 patients with COVID-19 severity information, thirteen (13/22, 59%) patients had ‘critical’ COVID-19, requiring mechanical ventilation/non-invasive ventilation, while eight had ‘severe’ COVID-19 and one patient had ‘mild’ COVID-19. In the 9 patients with available renal function data or creatinine value, 7 (78%) hadrenal failure on admission, including one patient who was on dialysis at the time of admission. Although neutrophil and lymphocyte counts were available in only 5 and 4 patients respectively, only one had neutropenia (neutrophil count < 500/microliter), and 3 had lymphocytopenia (total lymphocyte count < 1000/microliter). When Mucorales were identified to the genus level (13 patients), Rhizopus species were isolated in 10 (77%). [Table: Characteristics of the 41 patients with COVID-19 associated mucormycosis (CAMCR).] Sixteen patients (16/41, 39%) had ”concurrent” MCR, while the remaining patients (25/41) were diagnosed with MCR after a mean of 22 days (SD of 24). All but one patient with sequential MCR received systemic corticosteroids, while three of these patients received tocilizumab. Thirty-one of 41 patients (76%) had either rhino-orbital-cerebral (11, 27%), rhino-cerebral (3, 7%), or rhino-orbital disease (17, 41%), 3 (7%) had sinusitis alone, 3 (7%) had pulmonary MCR, and one each had cutaneous, palatal, gastrointestinal and disseminated MCR. Importantly, all 33 patients with DM had sinusitis, palatal, rhino-orbital, or rhino-orbital-cerebral disease. Co-infections were uncommon; 2 patients had a bacterial sinus infection (one with Pseudomonas and one with Staphylococcus aureus), and two had a sinus culture growing Aspergillus. MCR diagnosis was made antemortem in 39/41 (95%) and by autopsy in 2. For patients with antemortem diagnosis, MCR was established by biopsy in 31, and tissue culture in 18. In two patients who underwent postmortem, sequencing (2/2) and PCR (1/1) aided in the diagnosis. Of the 39 patients with antemortem MCR, amphotericin B-based treatment was administered in 38 (with posaconazole in 7 and with isavuconazole in 1). Of the 15 patients with information about the timing of anti-fungal therapy in relation to diagnosis of MCR, six received empiric treatment and nine following the diagnosis of MCR. Thirty-three (80%) of these patients underwent adjunct surgery (sinus and thoracic cavity debridement, orbital exenteration, decortication, and lung resection). In-hospital mortality was 49% (20/41), with an average time of death 19 days post-MCR diagnosis (information available only in 7 patients). 4. DISCUSSION Although our review is subject to publication biases, several observations emerged. First, MCR in patients with COVID-19 is a well-documented disease (41/47 of reported cases (87%) had documented MCR), in sharp contrast with the experience with CAPA. Specifically, the incidence of proven, or probable CAPA according to the recent ECMM/ISHAM consensus criteria [6] was only 6.1% in cohort CAPA studies that had a denominator [8]. Second, the majority of cases (71%) are reported from India. This finding is not surprising as India has the highest burden of MCR in the world with an estimated prevalence of 140 cases per million population [9]. Additionally, India has the second-largest number of adults aged 20–79 years with DM [10]. In fact, DM is the single most common risk factor for mucormycosis in India, being reported

Read the complete text